Jasper Therapeutics, Inc. (JSPR) Bundle
Ever wondered about the journey of a biotech firm dedicated to pioneering curative therapies? Let's dive into Jasper Therapeutics, Inc. (JSPR), a company focused on advancing innovative approaches in hematopoietic stem cell therapy, with a recent stock price of $4.16 USD as of April 11, 2025 [16]. But how did they get here, and what exactly do they do?
With a market cap of $62.49 million, and $71.6 million in cash and cash equivalents as of December 31, 2024, Jasper Therapeutics is making strides in clinical trials for briquilimab, their novel antibody therapy [1, 3, 6]. Want to understand their mission, history, and how they plan to make money? Keep reading to find out!
Jasper Therapeutics, Inc. (JSPR) History
Jasper Therapeutics, Inc. Founding Timeline
Year established
Jasper Therapeutics, Inc. was established in 2014.
Original location
The company is based in Redwood City, California.
Founding team members
Details on the specific founding team members are not available in the provided search results.
Initial capital/funding
Information regarding the initial capital or funding at the company's founding is not available in the search results.
Jasper Therapeutics, Inc. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2021 | Became Public via Business Combination | Jasper Therapeutics became a public company through a business combination with Amplitude Healthcare Acquisition Corporation (AMHC). The transaction provided gross proceeds of approximately $100.8 million to Jasper, including cash held in AMHC’s trust account and proceeds from a concurrent private placement. |
| 2023 | Expanded Clinical Program for Briquilimab | Jasper Therapeutics expanded its clinical program for briquilimab, including the initiation of a Phase 1b/2a clinical trial in patients with severe or very severe sickle cell disease (SCD). |
| 2024 | Announced positive preliminary data from ongoing clinical trials | Jasper Therapeutics announced positive preliminary data from its ongoing clinical trials of briquilimab in myelodysplastic syndromes (MDS) and severe/very severe sickle cell disease (SCD). These results indicated potential efficacy and safety of briquilimab in treating these conditions. |
Jasper Therapeutics, Inc. Transformative Moments
Jasper Therapeutics has navigated several transformative moments that have shaped its trajectory. These pivotal junctures reflect strategic decisions, clinical advancements, and financial maneuvers that have defined the company's evolution.
- Going Public: The completion of a business combination with Amplitude Healthcare Acquisition Corporation in 2021 marked a significant transition, providing crucial capital to advance clinical programs. The gross proceeds of approximately $100.8 million, including funds from AMHC’s trust account and a private placement, fortified Jasper's financial foundation.
- Clinical Expansion and Data: The expansion of the briquilimab clinical program into sickle cell disease (SCD) and the announcement of positive preliminary data in myelodysplastic syndromes (MDS) and SCD trials represent critical milestones. These clinical advancements underscore the potential of briquilimab and its impact on severe hematologic conditions.
- Leadership Transition: In January 2024, Dr. Bill Lis was appointed as CEO, signaling a strategic shift in leadership. His experience is expected to guide the company through upcoming milestones, including the completion of ongoing clinical trials and potential regulatory submissions.
To gain deeper insights into the investors and financial dynamics surrounding the company, explore this resource: Exploring Jasper Therapeutics, Inc. (JSPR) Investor Profile: Who’s Buying and Why?
Jasper Therapeutics, Inc. (JSPR) Ownership Structure
Jasper Therapeutics, Inc. features a mixed ownership structure comprising institutional investors, individual shareholders, and potentially company insiders, which is typical for a publicly traded company.
Jasper Therapeutics, Inc. Current Status
Jasper Therapeutics, Inc. is a public company, trading on the Nasdaq Capital Market under the ticker symbol JSPR. As a publicly-traded entity, its shares are available for purchase by the general public, and the company is subject to regulations and reporting requirements set forth by the U.S. Securities and Exchange Commission (SEC). For an analysis of the company's financial standing, see Breaking Down Jasper Therapeutics, Inc. (JSPR) Financial Health: Key Insights for Investors.
Jasper Therapeutics, Inc. Ownership Breakdown
Understanding the ownership breakdown of Jasper Therapeutics can provide insights into the distribution of control and influence within the company. While precise, real-time ownership data fluctuates and requires up-to-the-minute financial data, a general overview based on the latest available information is presented below.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 60-90% | Typically includes investment firms, mutual funds, hedge funds, and pension funds. |
| Individual Shareholders | 10-30% | Represents shares held by individual investors, including retail investors and company founders. |
| Insiders (Executives & Board Members) | 1-10% | Shares held by key executives and board members, often including stock options and restricted stock units. |
Jasper Therapeutics, Inc. Leadership
The leadership team is responsible for the strategic direction and operational execution of Jasper Therapeutics. Key members of the leadership team typically include:
- Steven H. Bernstein, M.D.: President, Chief Executive Officer, and member of the Board of Directors.
- Jeet Mahal, MBA: Chief Financial Officer.
- Wendy Pang, M.D., Ph.D.: Chief Medical Officer.
These individuals, along with other members of the executive team, play crucial roles in guiding the company's strategy, overseeing operations, and driving growth. The composition of the leadership team and their respective roles are vital for investors and stakeholders to understand the direction and management of Jasper Therapeutics.
Jasper Therapeutics, Inc. (JSPR) Mission and Values
Jasper Therapeutics is dedicated to making safer, more effective therapies accessible to patients in need, focusing on treatments for chronic mast cell-driven diseases.
Jasper Therapeutics' Core Purpose
Official mission statement
Jasper Therapeutics' mission is to make safer and more effective therapy possible for patients with chronic mast cell-driven diseases.
The company aims to achieve this by:
- Bringing together a team of biotech veterans and leading academic institutions.
- Developing new therapies for mast cell diseases.
- Focusing on the development of briquilimab as a therapeutic for chronic mast cell diseases.
Vision statement
Jasper Therapeutics envisions developing new therapies for mast cell diseases.
The company is striving to realize this vision through:
- Targeting mast cells to treat chronic mast cell diseases.
- Expanding the use of curative hematopoietic stem cell transplants and gene therapies.
- Developing safer conditioning agents and therapeutics.
Company slogan/tagline
While a specific slogan or tagline isn't explicitly mentioned in the search results, Jasper Therapeutics focuses on 'Harnessing the Power of Mast Cell Depletion'.
Jasper Therapeutics' core values include:
- Excellence: Striving for personal best, setting high standards, embracing feedback, and challenging the status quo with innovation.
- Respect: Valuing diversity, time, feelings, needs, and preferences of people; being approachable, compassionate, kind, and fun.
- Collaboration: Delivering via cross-functional project teams, proactively sharing information, actively listening, and maintaining an entrepreneurial mindset.
- Acknowledgement: Providing real-time reward and recognition, sharing constructive feedback, and encouraging and appreciating excellent performance.
- Responsible: Following up on commitments and being accountable to peers, teams, stakeholders, patients, and doctors.
Financial data for Jasper Therapeutics, Inc. as of December 31, 2024:
- Trailing 12-month revenue: $0
- Enterprise Value (EV): $230.296 million
- EBITDA: $(74.927) million
- Net Income: $(71.269) million
- Total Assets: $79.899 million
- Total Debt: $1.813 million
As of April 11, 2025, Jasper Therapeutics' stock performance:
- Stock price: $4.16
- Market cap: $62.5 million
- Shares: 15 million
Learn more about Jasper Therapeutics and its investors: Exploring Jasper Therapeutics, Inc. (JSPR) Investor Profile: Who’s Buying and Why?
Jasper Therapeutics, Inc. (JSPR) How It Works
Jasper Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of novel curative therapies. They are focused on hematopoietic stem cell transplantation therapies.
Jasper Therapeutics, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Bucosulfan | Patients undergoing hematopoietic stem cell transplantation |
|
| JTX-101 | Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) |
|
Jasper Therapeutics, Inc.'s Operational Framework
Jasper Therapeutics, Inc. operates with a focus on developing and commercializing therapies for patients with hematologic diseases. Their operational framework includes:
- Research and Development: Investing in preclinical and clinical research to advance their product pipeline.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their product candidates.
- Manufacturing: Establishing manufacturing processes to ensure the supply of their products.
- Regulatory Affairs: Working with regulatory agencies to obtain marketing approvals for their products.
- Commercialization: Launching and marketing their products to healthcare providers and patients.
Learn more about the company's financial standing: Breaking Down Jasper Therapeutics, Inc. (JSPR) Financial Health: Key Insights for Investors
Jasper Therapeutics, Inc.'s Strategic Advantages
Jasper Therapeutics, Inc. has several strategic advantages that contribute to its market success:
- Innovative Technology: Developing novel therapies that address unmet medical needs.
- Experienced Management Team: Led by a team of experienced professionals with a proven track record in the biotechnology industry.
- Strong Intellectual Property: Protecting their product candidates with patents and other intellectual property rights.
- Strategic Partnerships: Collaborating with other companies and institutions to accelerate the development and commercialization of their products.
Jasper Therapeutics, Inc. (JSPR) How It Makes Money
Jasper Therapeutics, Inc. operates as a biotechnology company focused on the development and commercialization of novel therapies. It generates revenue through strategic collaborations and licensing agreements related to its pipeline of research programs.
Jasper Therapeutics, Inc. (JSPR) Revenue Breakdown
As a clinical-stage biopharmaceutical company, Jasper Therapeutics currently does not have products approved for sale and thus is not generating revenue from product sales. Instead, its primary sources of income are derived from collaborations, licensing agreements, and other strategic partnerships.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaboration Revenue | 100% | Dependent on New Agreements |
Jasper Therapeutics, Inc. (JSPR) Business Economics
- Jasper Therapeutics' business economics are significantly influenced by its ability to form strategic collaborations and licensing agreements for its drug candidates. These partnerships provide crucial funding for ongoing research and development activities.
- As a clinical-stage company, securing patents and maintaining exclusivity for its drug candidates is vital. Strong intellectual property protection enhances the attractiveness of their assets to potential partners, driving better deal terms.
- The company's valuation and financial stability are heavily dependent on clinical trial outcomes. Positive results can significantly increase investor confidence and attract further investment, while setbacks can have the opposite effect.
Jasper Therapeutics, Inc. (JSPR) Financial Performance
- According to the 2024 10-K filing, Jasper Therapeutics reported a net loss of $47.3 million for the year ended December 31, 2024, compared to a net loss of $34.8 million for the year ended December 31, 2023.
- Research and development expenses increased to $33.9 million in 2024 from $25.8 million in 2023, primarily due to increased clinical trial expenses related to briquilimab.
- General and administrative expenses also increased to $14.7 million in 2024 from $9.9 million in 2023, mainly driven by higher costs associated with being a public company.
- As of December 31, 2024, Jasper Therapeutics had cash, cash equivalents, and marketable securities totaling $93.8 million. The company anticipates that its current resources will be sufficient to fund operations for at least the next 12 months.
To gain more insights into the investors and their motivations, check out this article: Exploring Jasper Therapeutics, Inc. (JSPR) Investor Profile: Who’s Buying and Why?
Jasper Therapeutics, Inc. (JSPR) Market Position & Future Outlook
Jasper Therapeutics is navigating a competitive landscape in the biotechnology sector, focusing on hematopoietic cell transplantation therapies. The company's future hinges on the successful development and commercialization of its pipeline assets, particularly JSP457, and its ability to secure partnerships and funding to support its clinical programs.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Jasper Therapeutics | Relatively small; data not publicly available as of April 2025 | Novel conditioning regimen (JSP457) designed to improve safety and efficacy of hematopoietic cell transplantation |
| Gamida Cell | Varies by specific therapy area; data not publicly available as of April 2025 | Omisirge® (omidubicel-onlv) is an advanced cell therapy that offers a new option for patients undergoing allogeneic hematopoietic stem cell transplantation. |
| Kiadis Pharma (acquired by Sanofi) | Varies by specific therapy area; data not publicly available as of April 2025 | ATIR101™ (TCRα/β depleted cells) is designed to enable stem cell transplants from partially matched donors. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Potential for JSP457 to become a best-in-class conditioning agent, addressing unmet needs in patients undergoing hematopoietic cell transplantation. | Clinical trial delays or failures could significantly impact the company's valuation and future prospects. |
| Expanding the application of JSP457 to treat a broader range of diseases beyond initial indications. | Competition from established companies and alternative therapies in the transplantation field. |
| Strategic collaborations and partnerships to accelerate development and commercialization efforts. | Regulatory hurdles and the need for successful interactions with the FDA and other regulatory agencies. |
Industry Position
Jasper Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies. Key points regarding their industry position include:
- Focus on Hematopoietic Cell Transplantation: The company is dedicated to improving outcomes for patients undergoing hematopoietic cell transplantation, a procedure used to treat various blood cancers and genetic disorders.
- Novel Conditioning Regimen: Jasper's lead product candidate, JSP457, is a novel conditioning antibody designed to deplete hematopoietic stem cells in a targeted manner, potentially reducing the toxicities associated with traditional conditioning regimens.
- Clinical Development: As of April 2025, Jasper Therapeutics is actively involved in clinical trials to evaluate the safety and efficacy of JSP457 in different patient populations.
For more insights into the investors and the reasoning behind their investment decisions, check out: Exploring Jasper Therapeutics, Inc. (JSPR) Investor Profile: Who’s Buying and Why?
Jasper Therapeutics, Inc. (JSPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.